ARTICLE | Finance
Stress test
How Frazier formed Outpost around a Takeda asset
March 21, 2016 7:00 AM UTC
Frazier Healthcare's latest round of asset sleuthing led the firm to a molecule from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) for stress urinary incontinence, which has no approved drugs in the U.S.
Frazier and the pharma formed Outpost Medicine to house OP-233, which has an undisclosed mechanism and has completed a Phase I trial for the indication. Takeda said OP-233 is outside its focus areas of cancer, gastroenterology and CNS diseases...